within Pharmacolibrary.Drugs.ATC.A;

model A10BD15
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.65,
    Cl             = 0.0005833333333333334,
    adminDuration  = 600,
    adminMass      = 1010 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.08,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BD15</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fixed-dose oral combination of metformin, a biguanide antihyperglycemic agent, and dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, used for the treatment of type 2 diabetes mellitus in adults. Both components work synergistically to improve glycemic control. This combination is approved and used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics estimated for healthy adult subjects as no direct clinical population PK model for the fixed-dose combination found in published literature. Individual PK parameters for metformin and dapagliflozin were considered based on referenced studies for the separate agents. Values here are pharmacologically reasonable estimates for a 1000 mg metformin and 10 mg dapagliflozin immediate-release oral combination, single dose, in adults.</p><h4>References</h4><ol><li><p>Dhillon, S (2019). Dapagliflozin: A Review in Type 2 Diabetes. <i>Drugs</i> 79(10) 1135–1146. DOI:<a href=&quot;https://doi.org/10.1007/s40265-019-01148-3&quot;>10.1007/s40265-019-01148-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31236801/&quot;>https://pubmed.ncbi.nlm.nih.gov/31236801</a></p></li><li><p>Donnan, K, &amp; Segar, L (2019). SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. <i>European journal of pharmacology</i> 846 23–29. DOI:<a href=&quot;https://doi.org/10.1016/j.ejphar.2019.01.002&quot;>10.1016/j.ejphar.2019.01.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30639796/&quot;>https://pubmed.ncbi.nlm.nih.gov/30639796</a></p></li><li><p>Boulton, DW, et al., &amp; LaCreta, F (2016). Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects. <i>Clinical therapeutics</i> 38(1) 99–109. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2015.11.010&quot;>10.1016/j.clinthera.2015.11.010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26682500/&quot;>https://pubmed.ncbi.nlm.nih.gov/26682500</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BD15;
